Current Treatment Approach to Treating EGFR mutant-NSCLC
Dr. Husain discusses how selecting between FLAURA-2, MARIPOSA, and other frontline regimens requires balancing efficacy, safety, and sequencing considerations to deliver the most personalized care in EGFR-mutant NSCLC.
Dr. Husain discusses how the growing number of frontline options for EGFR-mutant NSCLC demands a more strategic, personalized approach to therapy selection. He emphasizes that recent approvals for combination regimens provide exciting new possibilities but also raise important questions about toxicity, cost, and patient suitability. These advancements underscore the need to match each patient’s disease characteristics and clinical context with the optimal regimen.
Dr. Husain discusses how combination therapies are increasingly being considered as potential replacements for monotherapy in certain patients, particularly those at risk for early progression or CNS involvement. However, he acknowledges that monotherapy may remain appropriate for others based on performance status or comorbidities. The decision between FLAURA-2 and MARIPOSA regimens often hinges on their differing safety profiles, CNS activity, and emerging real-world evidence.
Dr. Husain discusses how treatment choice now requires deeper consideration of sequencing strategy from the outset, as early regimen decisions influence subsequent options. He concludes that an individualized, patient-centered approach—integrating efficacy, safety, and long-term planning—is essential for optimizing outcomes in this evolving therapeutic space.
